Biomarkers for the Early Detection and Treatment of Cancers
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1482
Interests: biomarkers; non-invasive diagnosis; inflammation; tumor biomarkers; neuroinflammation; specific proteins; neurodegeneration
Interests: biomarkers; non-invasive diagnosis; inflammation; tumor biomarkers; neuroinflammation; specific proteins
Special Issues, Collections and Topics in MDPI journals
The number of cancer cases is increasing every year. Prostate cancer is the most common cancer among men and breast cancer is the most common among women. However, a worrying phenomenon is the very large increase in the incidence of other types of cancer, including colorectal cancer and cancers of the urinary system. In developed countries, they are the second leading cause of death after cardiovascular diseases.
Rapidly developing cancer does not necessarily mean that the patient's prognosis is poor. Many of these cancers can be successfully treated. There is, however, a group of cancers that do not necessarily grow faster, but are detected late, only after metastasis. Cancers that are detected early and properly treated do not have to be a judgment against which there is no appeal. Taking into account the above, this Special Issue aims to highlight new findings regarding biomarkers that could improve the early detection of cancer patients and assess their potential clinical application in the rapid diagnosis in early stages of developing disease. Tumor markers can be used in screening for early detection of cancer or during treatment to monitor its effectiveness and staging the cancer.
We are pleased to invite you to submit research and review articles related to the aim of this Special Issue.
Prof. Dr. Barbara Mroczko
Dr. Monika Gudowska-Sawczuk
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- tumor biomarkers
- tumor progression
- early cancers
- inflammatory mediators
- early diagnosis